Preliminary data indicate that pCR correlates with excellent long-term outcomes in HER2+ breast cancer even when the neoadjuvant regimen is chemotherapy-sparing or otherwise non-standard7,8. The gene discussed is ERBB2; the disease is breast carcinoma.